Proctect Health Equity in Kidney Care
Background
Effective January 1, 2025, CMS plans to change coverage for oral-only phosphate lowering therapies (PLTs) drugs for patients with kidney failure. This could jeopardize patients’ access to vital medications and raise dialysis treatment costs. Introduced by Reps. Earl L. “Buddy” Carter, Ann McLane Kuster, Carol Miller, and Terri Sewell, the bipartisan Kidney PATIENT Act (H.R. 5074) aims to postpone this change until 2033 or until new intravenous therapies become available. State and National stakeholders from the kidney community and beyond have called on Washington to act quickly and exclude oral-only phosphate lowering therapies (PLTs) from the End Stage Renal Disease Prospective Payment System or ESRD Bundle.
Events
“Protecting Dialysis Patients with Kidney Failure”
Ensuring Access to Life-Saving ESRD Oral-Only Medicines within Medicare
Pilgram's Rest Baptist Church
Thursday, November 14 & Saturday, November 16, 2024
Chronic Kidney Disease | Screening | Treatment | Nutrition | Health Policy
Program 1 Agenda
Program 2 Agenda
In Partnership with
HEAL Collaborative and Ardelyx
Advocate
Help HEAL support the Kidney PATIENT Act (H.R. 5074) Sign the Petition.
Let Your Voice Be Heard!
Tell Congress to Protect Access to New Treatments for Patients
Resources
Past Programs
Thank you to our partners. Your commitment to change provides an abundance of hope.